The stock may react positively to the strong revenue growth and improved profitability, but investors should monitor the expected moderating growth in 2026 and await key clinical data readouts in H2 2026 for brenetafusp and HIV programs.
Price Chart
Executive Summary
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $400.0 million respectively, representing 24% and 29% year-over-year growth. The company reduced its net loss from $51.1 million in 2024 to $35.5 million in 2025 despite increased R&D spending, and ended the year with $864.2 million in cash. Management expects moderating revenue growth in 2026 as it awaits key clinical data readouts.
Key Financial Metrics
Key Facts
- KIMMTRAK net sales were $104.5 million in Q4 2025 (up 24% YoY) and $400.0 million for full year 2025 (up 29% YoY)
- Net loss improved to $35.5 million in 2025 from $51.1 million in 2024 despite higher R&D expenses
- Cash, cash equivalents and marketable securities totaled $864.2 million as of December 31, 2025
- R&D expenses increased to $274.9 million in 2025 from $222.2 million in 2024 due to autoimmune programs and Phase 3 trials
- Company expects moderating revenue growth in 2026 and anticipates key data readouts in second half of 2026
Financial Impact
$400 million in annual revenue with improving profitability and strong cash position
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| KIMMTRAK | $400.0M | +29.0% |
Risk Factors
- Management expects moderating revenue growth in 2026
- Key clinical data readouts in H2 2026 could impact the stock positively or negatively
- Increased R&D spending could pressure margins if not offset by revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-006721 |
| Document: ef20066378_8k.htm | 0001140361-26-006721 |
| Document: 0001140361-26-006721-index-headers.html | 0001140361-26-006721 |
| Document: 0001140361-26-006721-index.html | 0001140361-26-006721 |
| Document: 0001140361-26-006721.txt | 0001140361-26-006721 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $32.46 $32.18 | ▼ −0.86% | ▼ −0.97% | $29.71 (−8.47%) |
Aug 6, 2026 8w ago | 8-K | $34.50 $34.20 | ▼ −0.87% | ▼ −2.08% | $29.71 (−13.88%) |
May 31, 2026 17w ago | Press Release | $29.13 $28.29 | ▼ −2.88% | ▼ −0.13% | $29.71 (+1.99%) |
Apr 19, 2026 23w ago | Press Release | $31.46 $28.56 | ▼ −9.22% | ▼ −10.13% | $29.71 (−5.56%) |
Apr 8, 2026 25w ago | 144 | $31.85 $31.64 | ▼ −0.66% | ▼ −4.18% | $29.71 (−6.72%) |
Mar 17, 2026 28w ago | Press Release | $30.04 $30.28 | ▲ +0.80% | ▲ +1.51% | $29.71 (−1.10%) |
Feb 25, 2026 31w ago | 8-K | $32.16 $33.73 | ▲ +4.88% | ▲ +5.98% | $29.71 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access